Edwards Lifesciences Co. (NYSE:EW) VP Sells $437,700.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,108,777.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $87.29 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm’s 50-day moving average is $87.76 and its two-hundred day moving average is $83.71. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a market capitalization of $52.60 billion, a PE ratio of 37.63, a price-to-earnings-growth ratio of 3.21 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently bought and sold shares of the company. Maxwell Wealth Strategies Inc. increased its position in shares of Edwards Lifesciences by 481.8% during the first quarter. Maxwell Wealth Strategies Inc. now owns 20,811 shares of the medical research company’s stock valued at $1,829,000 after acquiring an additional 17,234 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of Edwards Lifesciences by 94.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 102,272 shares of the medical research company’s stock valued at $9,773,000 after acquiring an additional 49,751 shares during the last quarter. Cetera Advisors LLC increased its position in shares of Edwards Lifesciences by 175.1% during the first quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after acquiring an additional 24,242 shares during the last quarter. Cetera Investment Advisers increased its position in shares of Edwards Lifesciences by 207.0% during the first quarter. Cetera Investment Advisers now owns 145,840 shares of the medical research company’s stock valued at $13,936,000 after acquiring an additional 98,338 shares during the last quarter. Finally, PGGM Investments acquired a new stake in shares of Edwards Lifesciences during the first quarter valued at about $208,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Deutsche Bank Aktiengesellschaft raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $86.00 to $103.00 in a report on Tuesday, May 14th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a report on Friday, April 26th. The Goldman Sachs Group began coverage on shares of Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 price objective on the stock. Finally, Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.